Perjeta (Pertuzumab) Injection - 420mg Single-Use Vial for Intravenous Infusion
Perjeta (Pertuzumab) Injection - 420mg Single-Use Vial for Intravenous Infusion
- Description (Brief)
- (From box) Dilute prior to use; for intravenous infusion only; single-use vial; discard unused portion
- (From insert)
- PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
- Location
- Currently not on view
- Object Name
- pharmaceutical
- biological
- date made
- ca 2013
- product expiration date
- 2014-02
- maker
- Genentech, Inc.
- place made
- United States: California, South San Francisco
- Physical Description
- plastic (overall material)
- glass (overall material)
- metal (overall material)
- cardboard (overall material)
- pertuzumab, 420mg/14 mL (overall ingredient)
- Measurements
- overall: 1 3/4 in x 2 3/4 in x 3 1/8 in; 4.445 cm x 6.985 cm x 7.9375 cm
- overall: 3 in x 2 1/8 in x 2 1/8 in; 7.62 cm x 5.3975 cm x 5.3975 cm
- ID Number
- 2013.0069.09
- catalog number
- 2013.0069.09
- accession number
- 2013.0069
- Credit Line
- Gift of Genentech, Inc.
- subject
- Women's Health
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- Antibody Initiative: Monoclonal Antibodies
- Data Source
- National Museum of American History
Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.
If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.
Note: Comment submission is temporarily unavailable while we make improvements to the site. We apologize for the interruption. If you have a question relating to the museum's collections, please first check our Collections FAQ. If you require a personal response, please use our Contact page.